Evidence map›Paper›PMID 26911141›Full record

ArticleBMC cancer2016

RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines.

Rashmi Narendrula, Kyle Mispel-Beyer, Baoqing Guo, Amadeo M Parissenti, Laura B Pritzker, Ken Pritzker, Twinkle Masilamani, Xiaohui Wang, Carita Lannér

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03524430 (RNA Disruption Assay), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03524430 naactive not recruitingnot on this mapstarted 2018, after this paper: background citation

RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy (BREVITY / BREVITY-02 in Germany)

TypeinterventionalSponsorRna Diagnostics Inc.Ran2018 to 2031Enrolled801ConditionsBreast Neoplasm FemaleArmsCore needle biopsy
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Rashmi NarendrulaDepartment of Biology, Laurentian University, Sudbury, ON, Canada.
Kyle Mispel-BeyerDepartment of Chemistry and Biochemistry, Laurentian University, Sudbury, ON, Canada.
Baoqing GuoAdvanced Medical Research Institute of Canada, Sudbury, ON, Canada.
Amadeo M ParissentiDepartment of Biology, Laurentian University, Sudbury, ON, Canada.
Laura B PritzkerRNA Diagnostics Inc., Toronto, ON, Canada.
Ken PritzkerRNA Diagnostics Inc., Toronto, ON, Canada.
Twinkle MasilamaniRNA Diagnostics Inc., Toronto, ON, Canada.
Xiaohui WangRNA Diagnostics Inc., Toronto, ON, Canada.
Carita LannérDepartment of Biology, Laurentian University, Sudbury, ON, Canada. clanner@nosm.ca.
Laurentian University · CAUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCellular stressors and apoptosis-inducing agents have been shown to induce ribosomal RNA (rRNA) degradation in eukaryotic cells. Recently, RNA degradation in vivo was observed in patients with locally advanced breast cancer, where mid-treatment tumor RNA degradation was associated with complete tumor destruction and enhanced patient survival. However, it is not clear how widespread chemotherapy induced "RNA disruption" is, the extent to which it is associated with drug response or what the underlying mechanisms are.

methodsOvarian (A2780, CaOV3) and breast (MDA-MB-231, MCF-7, BT474, SKBR3) cancer cell lines were treated with several cytotoxic chemotherapy drugs and total RNA was isolated. RNA was also prepared from docetaxel resistant A2780DXL and carboplatin resistant A2780CBN cells following drug exposure. Disruption of RNA was analyzed by capillary electrophoresis. Northern blotting was performed using probes complementary to the 28S and 18S rRNA to determine the origins of degradation bands. Apoptosis activation was assessed by flow cytometric monitoring of annexin-V and propidium iodide (PI) binding to cells and by measuring caspase-3 activation. The link between apoptosis and RNA degradation (disruption) was investigated using a caspase-3 inhibitor.

resultsAll chemotherapy drugs tested were capable of inducing similar RNA disruption patterns. Docetaxel treatment of the resistant A2780DXL cells and carboplatin treatment of the A2780CBN cells did not result in RNA disruption. Northern blotting indicated that two RNA disruption bands were derived from the 3'-end of the 28S rRNA. Annexin-V and PI staining of docetaxel treated cells, along with assessment of caspase-3 activation, showed concurrent initiation of apoptosis and RNA disruption, while inhibition of caspase-3 activity significantly reduced RNA disruption.

conclusionsSupporting the in vivo evidence, our results demonstrate that RNA disruption is induced by multiple chemotherapy agents in cell lines from different tissues and is associated with drug response. Although present, the link between apoptosis and RNA disruption is not completely understood. Evaluation of RNA disruption is thus proposed as a novel and effective biomarker to assess response to chemotherapy drugs in vitro and in vivo.

Indexed as

Antineoplastic AgentsApoptosisBreast NeoplasmsCarboplatinCaspase 3Cell Line, TumorDocetaxelDose-Response Relationship, DrugDrug Resistance, NeoplasmFemaleHumansMCF-7 CellsOvarian NeoplasmsRNA, Ribosomal, 18SRNA, Ribosomal, 28SRNA StabilityAntineoplastic AgentsCarboplatinCaspase 3DocetaxelRNA, Ribosomal, 18SRNA, Ribosomal, 28STaxoids

Identifiers

PMID26911141
PMCPMC4765116
OpenAlexW2284723470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.